The Food and Drug Administration (FDA) said zuranolone, sold under the brand name Zurzuvae, has been approved as a once-daily pill taken for two weeks.
Until now, treatment for postpartum depression (PPD) was available only as an intravenous injection, the FDA said. BBC News
See also:
- FDA Approves First Oral Treatment for Postpartum Depression US Food and Drug Administration
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial (open access) JAMA Psychiatry
No comments:
Post a Comment